A novel injectable peptide-based hydrogel for myocardial infarction treatment

点击翻译按钮获取中文摘要

Recently, injection of bio-derived hydrogels into myocardial infarction have been investigated for the novel treatment for left ventricular remodeling. In this study, a novel thermoresponsive peptide-type injectable gel matrix composed of naturally occurring sequences were developed, and their therapeutic efficiency was evaluated. A small peptide, Ac-(RVEIKVDI) 2-CONH2 which mimics an anti-parallelβ-sheet region ofβ2-microblobulin, forms hydrogel in situ with high water content in 10v% DMSO aqueous solution. Its solution formed hydrogel in approximately 3 minutes at room temperature. Hydrogelation of the peptide solution is driven by electrostatic and hydrophobic interaction with the conformational change from random coil toβ-sheet structure, as assumed from FT-IR measurement. This hydrogel is rigid(G'> 300 Pa) and is not disrupted in PBS for over 24 hours. In addition, the peptide solution is easily injected into the body by syringe with thin needle, and the resultant hydrogel did not result in serve inflammation. This peptide hydrogel may have implication for in situ forming biomaterials. In addition, we confirmed that the injection of biodegradable hydrogel into the myocardial infarction is as effective as the previous non-degradable one may be via a different mechanism.